Barclays analyst Steve Valiquette lowered the firm’s price target on CVS Health to $110 from $118 and keeps an Overweight rating on the shares following the Oak Street acquisition and Q4 results. The firm views the company’s 2023 outlook as mixed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CVS: